Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT

In this retrospective study, we evaluated the benefit of repeated carbon 11 (C11)-acetate positron emission tomography/computed tomography (PET/CT) to assess response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA).A total of 30 patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medicine (Baltimore) 2016-08, Vol.95 (31), p.e4308-e4308
Hauptverfasser:	Farnebo, Jacob, Wadelius, Agnes, Sandström, Per, Nilsson, Sten, Jacobsson, Hans, Blomqvist, Lennart, Ullén, Anders
Format:	Artikel
Sprache:	eng
Schlagworte:	Abiraterone Acetate - administration & dosage Acetates Administration, Oral Aged Antineoplastic Agents - administration & dosage Carbon Cohort Studies Disease-Free Survival Dose-Response Relationship, Drug Drug Administration Schedule Follow-Up Studies Humans Kaplan-Meier Estimate Male Medicin och hälsovetenskap Middle Aged Observational Study Positron Emission Tomography Computed Tomography - methods Predictive Value of Tests Prostatic Neoplasms, Castration-Resistant - diagnosis Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - mortality Retrospective Studies Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!